Study Aims to Increase Adoption of Advanced Diabetes Technology in Young People with Type 1 Diabetes

JDRF Canadian Clinical Trial Network launches Markham site of clinical trial for children and adolescents living with type 1 diabetes

Markham, ON (April 27, 2012) – JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce the launch of the Markham site of the first multi-centre pediatric study in Canada using insulin pump therapy and continuous glucose monitoring (CGM). The Markham site will be led by Dr. Susan Kirsch, JDRF CCTN researcher and pediatric endocrinologist, Markham Stouffville Hospital; the study’s principal investigator is Dr. Margaret Lawson at the Children’s Hospital of Eastern Ontario (CHEO) in Ottawa. Overall, the study – Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes Trial (CGM TIME Trial) – will involve 128 children and teenagers aged five to 18 years old with type 1 diabetes (T1D). The goal of the study is to find better ways for youths to manage the disease, and in particular, determine the best times to introduce CGM to this age group.

CGM devices provide both a real-time snapshot of the glucose levels of a person with diabetes, as well as trend information on whether glucose is moving upwards or downwards, and how fast. The devices also provide warnings when the glucose is becoming too high or too low. JDRF’s landmark CGM trials have shown that CGMs can significantly improve diabetes control and decrease the frequency of high and low blood sugars when used regularly. However, a significant number of children in the studies, and particularly teens and young adults, did not use the CGM devices consistently.

“While insulin pump therapy is popular among children, teens, and their parents, the majority of pediatric pump users do not achieve adequate diabetes control, which means they are still at risk of developing diabetes-related complications in later years,” said Dr. Lawson, pediatric endocrinologist, CHEO. “What’s more, recent studies have shown that even testing blood glucose levels 10 times per day isn’t enough; in the periods between testing, many children still experience highs and lows which affect their diabetes control and their sense of well-being.”

“The CGM TIME Trial is significant to our clinical practice because it is important for us to determine the best point in time to initiate CGM in addition to pump therapy,” said Dr. Kirsch. “The benefit to the children and teens in our program will be essential for us to provide optimal care in the future.” “Over three million Canadian children, adolescents, and adults live with some form of diabetes – more than 300,000 of which are living with type 1 diabetes. This number is increasing by three to five per cent annually, and the greatest rise is being seen in children five to nine years of age,” said Andrew McKee, President and CEO of JDRF Canada. “This study will explore how children with type 1 diabetes, their parents, and their health care team can optimally manage their disease so that kids can have the best quality of life while reducing the risk of complications.”

The addition of CGM to pump therapy is central to the development of an artificial pancreas system—an automated closed-loop system which would disperse insulin based on real-time changes in blood sugar levels. The artificial pancreas would enable people living with T1D to maintain blood sugar levels within the normal
range with minimal effort, resulting in better quality of life and lower risks of complications (www.artificialpancreasproject.com).

"Our government’s support to JDRF is helping to position our scientists at the forefront of world-class research and new cures and therapies, the results of which will have a positive impact on people living with diabetes in Canada and around the world,” said Mark Adler, Member of Parliament for York Centre, on behalf of the
Honourable Gary Goodyear, Minister of State for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario). “Through investments like this, our government is committed to jobs, growth, and long-term prosperity in southern Ontario.”

The study is being led by CHEO with participation from four other Ontario pediatric diabetes centres: Markham Stouffville Hospital, McMaster Children’s Hospital, The Hospital for Sick Children (SickKids), and the Children's Hospital at London Health Sciences Centre.


About JDRF

JDRF is the leading global organization focused on T1D research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Since its founding in 1970 (1974 in Canada), JDRF has awarded more than $1.6 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. For more information, please visit www.jdrf.ca.

About JDRF CCTN

JDRF CCTN is supported by the Government of Canada, which committed $20 million through the Federal Economic Development Agency for Southern Ontario’s Southern Ontario Development Program in 2009, and JDRF, which provided an additional $13.9 million. The $33.9 million investment will help accelerate the testing of new technologies and treatments for Canadians and individuals around the world living with T1D and its complications.

JDRF CCTN is a groundbreaking effort to accelerate solutions for the management, care and cure of T1D. JDRF CCTN is currently developing several high-profile clinical trials, in association with leading diabetes researchers at partner universities and medical centres in southern Ontario. The goal is to position southern Ontario as an international hub for diabetes translational research, innovation, and commercialization of new therapeutics and enabling technologies. For more information, please visit www.jdrf.ca/cctn.

For more information about the CGM TIME Trial, or to schedule an interview, please contact:
Jennifer Dolan
JDRF Canadian Clinical Trial Network
647.789.2012
[email protected]

Lets turn type one into type none